Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Assets (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Current Assets for 9 consecutive years, with $619.1 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 27.68% year-over-year to $619.1 million; the TTM value through Mar 2026 reached $619.1 million, down 27.68%, while the annual FY2025 figure was $682.9 million, 26.46% down from the prior year.
  • Current Assets hit $619.1 million in Q1 2026 for Bicycle Therapeutics, down from $682.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.0 billion in Q2 2024 and bottomed at $369.4 million in Q4 2022.
  • Average Current Assets over 5 years is $628.5 million, with a median of $603.0 million recorded in 2023.
  • Year-over-year, Current Assets surged 151.76% in 2024 and then dropped 27.68% in 2026.
  • Bicycle Therapeutics' Current Assets stood at $369.4 million in 2022, then skyrocketed by 52.11% to $561.9 million in 2023, then soared by 65.27% to $928.6 million in 2024, then fell by 26.46% to $682.9 million in 2025, then decreased by 9.34% to $619.1 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $619.1 million, $682.9 million, and $738.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.